Substance / Medication

Sparfloxacin

Overview

Active Ingredient
sparfloxacin
RxNorm CUI
18469

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
[Etiotropic therapy with sparfloxacine in ENT practice].
Luchikhin L A, Troitskiĭ S A · Vestn Otorinolaringol · 2005
PMID: 16353009RCT
[Sparfloxacin in combined therapy for pulmonary tuberculosis].
Sokolova G B, Khaĭmenova T Iu, Lazareva Ia V et al. · Antibiot Khimioter · 2008
PMID: 19069178Trial
Pharmacokinetics of sparfloxacin in broiler chicken.
Sriranjani D, Kalaiselvi L, Ramesh S et al. · Br Poult Sci · 2006
PMID: 17190680Trial
A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity.
Dawe R S, Ibbotson S H, Sanderson J B et al. · Br J Dermatol · 2003
PMID: 14674902Trial
Ethyl cellulose and polyethylene glycol-based sustained-release sparfloxacin chip: an alternative therapy for advanced periodontitis.
Parthasarathy V, Manavalan R, Mythili R et al. · Drug Dev Ind Pharm · 2002
PMID: 12236071Trial
[Sparfloxacin (Sparflo) in the treatment of urological infections].
Lopatkin N A, Derevianko I I, Lavrinova L N et al. · Antibiot Khimioter · 2002
PMID: 12077935Trial
[Multicenter evaluation on the efficacy and safety of sparfloxacin in the treatment of acute bacterial infections].
Cai Yongning, Liang Derong, Xu Nan et al. · Hua Xi Yi Ke Da Xue Xue Bao · 2002
PMID: 12575213Trial
The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.
Kamberi M, Nakashima H, Ogawa K et al. · Br J Clin Pharmacol · 2000
PMID: 10671902TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sparfloxacin (substance)
SNOMED CT
387554008
UMLS CUI
C0052585
RxNorm CUI
18469

Clinical Data

This intervention maps to 14 entities in the Ltrl knowledge graph.

9
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.